1 Affordability of Insulin," which was sponsored by the American Association of Clinical 2
Endocrinologists (AACE) and the Endocrine Society (ES), and which directed the American 3
Medical Association (AMA) to: 4 5 (1) work with relevant medical specialty societies to convene a summit with participation by 6 patients, clinicians, manufacturers, pharmacy benefit managers (PBMs), insurers and the 7 appropriate federal representatives to highlight the dramatic increase in insulin costs and 8 identify potential solutions; (2) pursue solutions to reduce patient cost sharing for insulin and 9 ensure patients benefit from rebates at the point of sale; (3) work with health insurance 10 companies and federal agencies to stabilize drug formularies and reduce non-medical switching 11 by encouraging plans to cover insulin products at the same cost listed on a drug formulary 12 throughout the entire plan year; (4) encourage insulin price and cost transparency among 13 pharmaceutical companies, PBMs and health insurance companies; and (5) work with 14 electronic medical record vendors and insurance companies to integrate current formularies and 15 price information into all systems so physicians and patients can make informed decisions on 16 insulin products to reduce cost burdens on patients. 17 18 The Board of Trustees assigned this item to the Council on Medical Service for a report back to the 19 House of Delegates at the 2018 Annual Meeting. This report highlights insulin as one among the 20 many prescription drugs to recently experience exceptional price increases, government and legal 21 actions to address insulin affordability, opportunities to identify more affordable options for 22 patients in need, and the strong ongoing efforts of the AMA to address affordability of 23 pharmaceuticals. Finally, this report presents policy recommendations. 24 25 BACKGROUND 26 27 Approximately 30 million Americans have diabetes, 1 and approximately six million Americans use 28 insulin. 2 As explained by the AACE and the ES, patients with type 1 diabetes need insulin for 29 survival and frequently insulin is the only drug that can control the diabetes of patients with type 2 30 diabetes. 3 Insulin can be very expensive, and the price has increased dramatically over the course 31 of the past decade. For example, the annual retail price of Humulin R (U-500) 500 units/mL-an 32 insulin marketed by Eli Lilly and Company (Lilly)-increased from $2,487 at the end of 2005 to 33 $15,860 by the end of 2015. 4 Humulin is one of six brand-name drugs that increased in price by 34 500 percent or more from 2006 to 2015. 5 In general, the mean price per milliliter of insulin 35 increased almost 200 percent, from $4.34 per milliliter in 2002 to $12.92 per milliliter in 2013.
High insulin prices impact stakeholders throughout the health care system. Of course, uninsured 1 patients paying cash for their prescriptions are exposed directly to high insulin prices. Insured 2 patients are also directly impacted by high insulin prices when they are still in the deductible 3 period, when the drug prescribed is not covered by their insurance, when a nonpreferred formulary 4 status for a particular insulin product leads to a higher patient cost-share, and when a Medicare Part 5 D beneficiary is in the "donut hole." 7 As the number of patients enrolled in high-deductible health 6 plans and Medicare Part D continues to rise, more patients will be vulnerable to significant drug 7 prices. Insulin prices also impact health plans/payers and PBMs. The impact of insulin 8 expenditures on Medicare and Medicaid has been noteworthy. For example, expenditures for just 9 one long-acting insulin analogue, glargine, were the second largest of all Medicare expenditures in 10 2015. 8 In that year, Medicare Part D spent more than $4.3 billion and Medicaid spent more than 11 $1.4 billion on glargine alone. 9 12 13 Pharmaceutical manufacturers, PBMs and others in the pharmacy supply chain continue to blame 14 each other for high drug prices, 10 but some have taken steps that may ameliorate the impact on 15 patients. For example, Novo Nordisk has indicated that it would limit future annual price increase 16 percentages to not exceed single digits, ensure that a lower-priced option for human insulin remains 17 available, and continue support of copay assistance and patient assistance programs, which are 18 described later in this report.
11 19 20 At the same time, it is important to emphasize that insulin is one of the many essential drugs across 21 all categories of pharmaceuticals-brand name, specialty, and generic-to experience remarkable 22 price increases. For example, the brand name drug Wellbutrin XL, used to treat depression, 23 experienced a price increase of 1,185 percent over a ten-year study period ending in 2015. 12 Over 24 the same ten-year study period, the specialty drug Enbrel, used to treat inflammatory and 25 immunological disorders, experienced a 172 percent price increase. 13 Finally, between 2010 and 26 2015, the generic drug divalproex sodium, an anticonvulsant, experienced a price increase of 450. 6 27 percent. 14 The Council acknowledges that, as with insulin, if patients are not able to take these 28 medications correctly due to affordability, complications can result. 29 30 GOVERNMENT AND LEGAL ACTIONS TO ADDRESS INSULIN AFFORDABILITY 31 32 The significant and complicated factors contributing to increases in insulin prices have led both 33 state and federal governments, as well as private citizens, to take formal action. To date, at least 34 five states and a federal prosecutor are demanding information from insulin manufacturers and 35
PBMs. 15 In addition, prominent class-action attorneys are bringing lawsuits on behalf of patients. following a change to FDA law in 2020). 34 As with other drugs, the price patients will pay for 12
Basaglar varies depending on their health insurance plan. 35 Additionally, Basaglar experienced 13 uptake that varied based on patients' insurance type. 36 37 38 In fact, the proportion of patients using more expensive, newer insulin analogs has substantially 39 increased, even though data suggests that there is "little clinical benefit" to using insulin analog 40 versus regular human insulin and neutral protamine Hagerdorn (NPH) for type 2 diabetes. 44 In 41 2000, 19 percent of privately insured adults with type 2 diabetes were using analog insulin, but by 42 2010, 96 percent of that population was using insulin analogs. 45 The older insulins, however, are 43 still considered to be as effective as the analogs in controlling blood glucose for most patients with 44 type 2 diabetes. 46 Moreover, a vial of NPH (N), human regular (R), or premixed 70/30 N/R insulin 45 (Novolin N, R, or 70/30) can be obtained for as little as $25. 47 At the same time, given the 46 substantial increase in use of insulin analogs since 2000, younger clinicians may not be as well 47 versed in the use of older insulins, with many training programs no longer emphasizing the use of 48 human insulins. 48 Accordingly, guidance and educational materials can help younger physicians 49 become more comfortable with prescribing more affordable insulin alternatives. 49 Consistent with 50 these recommendations, a recent study compared prescription drug spending in the US to nine 51 other high-income countries and found that US citizens consume a mix of drugs that include a high 1 proportion of newer, more expensive medications without evidence of better health outcomes than 2 the other nine countries examined. 50 The study observed that, unlike the US, the other nine 3 countries have processes to assess not just whether a new drug is effective, but whether it is more 4 effective than existing therapies, and sometimes, whether it is cost-effective. 51 A process for 5 including cost-effectiveness in comparative effectiveness research for pharmaceuticals is consistent 6
with AMA Policy H-110.986, which is detailed in the policy section below. 7 8
Improving Price Transparency 9 10
With timely, accurate information about what a specific prescription will cost a specific patient, 11
physicians and patients will be in a stronger position to jointly develop optimal treatment plans. As 12 detailed below, the AMA is engaged in significant activity, supported by longstanding policy, to 13 advocate for improved prescription drug price transparency. Improved transparency at the point of 14 sale may also help patients address affordability concerns. 15 16 Many health care industry stakeholders can potentially help improve insulin affordability. In 17
November 2017, Surescripts announced a Real-Time Prescription Benefit to advance this goal. 18 Surescripts is collaborating with six electronic health records (EHR) companies (representing 53 19 percent of the US physician base) and leveraging information from PBMs CVS Health and Express 20
Scripts (representing nearly two-thirds of US patients), "to deliver patient-specific benefit and price 21 information to providers in real time at the point of care. Once integrated with the EHR, the 22 solution will also display therapeutic alternatives so that the prescriber and patient can collaborate 23 in selecting a medication that is both clinically appropriate and affordable." 52 UnitedHealthcare 24 and OptumRx are collaborating to provide a similar tool, specifically for their enrollees. 53 With 25
PreCheck MyScript, before prescribing a medication, physicians can run a pharmacy trial claim to 26 see how much a patient would be charged for a specific medication. The system will also provide 27 lower-cost alternatives, when available. 28 29 In addition, pharmacists play an important role. Pharmacists may be aware of less expensive 30 prescription drug options, but pharmacists can be prevented from informing patients of these 31 options due to certain provisions in their contracts with PBMs. 54 For example, a drug formulary can 32 require patients to spend more on a prescription copay than they would be charged if they 33 purchased the drug without insurance. 55 So called "gag clauses" in pharmacy-PBM contracts can 34 bar pharmacists from telling consumers about less expensive options, such as not using their 35 insurance. Moreover, "clawback" provisions can allow PBMs to take back the difference between a 36
higher copay amount and a lower negotiated rate. Bipartisan bills have recently been introduced in 37 both the Senate 56 and the House 57 to prohibit these restrictions on pharmacies and pharmacists. 38 39 Additionally, financial assistance programs can help eligible patients, but as the ES has explained, 40 these programs are often inaccessible or overly complicated for the patients who need them the 41 most. 58 For example, the Novo Nordisk Savings Card can help patients save hundreds of dollars on 42 their diabetes medication. 59 However, to be eligible for this program, patients must be enrolled in a 43 commercial insurance plan (patients paying cash and those insured through any federal or state 44 plan are ineligible). 60 Additionally, the discount only applies for up to 24 months, and is subject to 45 maximum benefit limitations. 61 Sanofi-Aventis similarly offers a Sanofi Rx Savings Card, but it 46 too carries eligibility restrictions that are not easily found on its website. 62 Finally, Lilly offers 47 limited time offers for discounts on insulin products, but each offer is subject to eligibility 48 requirements and differing expiration dates. 63 
49
Some patients may benefit from other forms of financial assistance, but this too is complicated. 1
Patients without health insurance or without prescription drug coverage can apply for patient 2 assistance programs, and the nonprofit NeedyMeds can help patients find programs that offer free 3 or low-cost insulin for those who meet eligibility requirements. 64 Some patients who have 4 prescription drug coverage, especially those with high deductible health plans, may find that cash 5 and coupon prices can be lower than their insurance copay or coinsurance. 65 Websites like GoodRx 6 can help patients find the lowest prices for their insulin. 66 However, companies that provide health 7 insurance and prescription drug coverage have started instituting "copay accumulators," which can 8 significantly impact patients' out-of-pocket costs when using drug coupons. 67 Previously, when 9 patients used copay coupons to reduce the price they pay for their prescriptions, the value of those 10 coupons counted toward their deductible or out-of-pocket maximum. However, the new copay 11 accumulators will not count the coupons' value toward helping patients spend down their 12 deductibles and out-of-pocket maximum. Accordingly, once patients use the full value of their drug 13 coupons, they will be subject to more of the cost than they had been before. 68 Moreover, some 14 insurance companies limit insured patients' abilities to use prescription coupons at all. The market factors contributing to the insulin price increases are complex and span the 25 pharmaceutical supply chain. Pursuant to Policy H-110.992, the AMA is committed to monitoring 26 the relationships between PBMs and the pharmaceutical industry and strongly discouraging 27 arrangements that could cause a negative impact on the cost or availability of essential drugs. In 28 addition, Policy H-110.987 supports legislation that authorizes the Attorney General and/or the 29 FTC to take legal action to address price gouging by pharmaceutical manufacturers and increase 30 access to affordable drugs for patients. Building upon these policies, the Council recommends that 31 the AMA encourage the FTC and DOJ to monitor insulin pricing and market competition and take 32 enforcement actions, as appropriate. 33 34 As demonstrated by the extensive policy and activity summarized in this report, the AMA is deeply 35 committed to efforts to improve prescription drug affordability in general, and insulin affordability, 36 in particular. In addition to supporting the FTC and DOJ, the AMA has established policy that 37 supports the FDA as it strives to increase access to high quality generic and biosimilar drugs. 38 Specifically, under Policy H-100.980, the AMA affirms its commitment to continuing to work with 39 the FDA on controversial issues concerning drugs, biologics and pharmaceuticals to try to resolve 40 concerns of physicians. 41 42 VBID presents a powerful opportunity to reduce patient cost-sharing for high-value services, such 43 as diabetes treatment, and AMA policy strongly supports this model. Policy H-185.939 outlines 44 principles to guide the design and implementation of VBID programs, including that VBID 45 explicitly consider the clinical benefit of a given service or treatment when determining cost-46 sharing or other benefit design elements. Policy H-110.986 specifically supports value-based 47 pricing for pharmaceuticals, and Policy H-155.960 encourages third-party payers to use targeted 48 benefit design, with cost-sharing requirements determined based on the clinical value of a health 49 care service, with consideration given to patient income and other factors known to impact 50 compliance. Similarly, Policy H-110.990 states that cost-sharing requirements for prescription 51 drugs should be based on considerations such as the unit cost of medication, availability of 1 therapeutic alternatives, medical condition being treated; personal income, and other factors known 2 to affect patient compliance. In addition, the policy supports joint physician-patient decision-3 making, encouraging the development and use of technology to enable physicians and patients to 4 determine the actual price and out-of-pocket costs of prescription drugs prior to making prescribing 5 decisions. 6 7 In recent years, the AMA has demonstrated an ongoing commitment to improving prescription 8 drug price transparency. As detailed above, the TruthinRx campaign continues a powerful 9 grassroots campaign for greater transparency in prescription drug pricing, and the AMA Model Act 10 specifically responds to Policy H-110.987, which encourages prescription drug price and cost 11 transparency among pharmaceutical companies, PBMs, and health insurance companies. Moreover, 12 pursuant to Policy H-110.987, the AMA supports drug price transparency legislation that requires 13 pharmaceutical manufacturers to provide public notice before increasing the price of any drug 14 (generic, brand, or specialty) by 10 percent or more each year or per course of treatment and 15 provide justification for the price increase. Similarly supporting transparency and collaboration 16 across the pharmacy supply chain, Policy H-125.979 supports AMA efforts to encourage PBMs, 17 health insurers, and pharmacists to enable physicians to receive accurate, real-time formulary data 18 at the point of prescribing. In this way, health care technology and shared information can promote 19 optimal physician-patient joint decision making. Together, these efforts are accomplishing the 20 goals of Resolution 826-I-17. As a logical next step, the Council recommends that the AMA 21 disseminate the model state legislation it has developed to promote increased drug price and cost 22 transparency and to prohibit "clawbacks" and standard gag clauses in contracts between 23 pharmacies and PBMs that bar pharmacists from telling consumers about less expensive options, 24 such as choosing to pay cash rather than using insurance, to purchase their medication. Moreover, 25 the Council recommends that the AMA provide assistance upon request to state medical 26 associations in support of state legislative and regulatory efforts addressing drug price and cost 27 transparency. 28 29 The Council also thanks the AACE and the ES for their expertise and for calling attention to the 30 need for training on the appropriate use of regular human insulin and neutral protamine Hagerdorn 31 for post-graduate physicians, fellows, residents, and students. The Council recommends that the 32 AMA support initiatives, such as those by AACE, ES, and other national medical specialty 33 societies, that strive to fill this gap in continuing medical education. Similarly, to help physicians 34 better understand the complex challenges their patients may face in paying for their medication, the 35 Council recommends that the AMA support physician education regarding drug price and cost 36 transparency and challenges that arise at the pharmacy. 37 38 As described above, it is important to continue to view insulin affordability within the context of 39 the much broader issue of prescription drug affordability in the US. The AMA has a deep and 40 longstanding commitment to improving patient access to affordable prescriptions. Recognizing that 41 access to critical drugs across many critical disease states is jeopardized by high prices and 42 continued price increases, the AMA has made a strategic decision to work toward broad-based 43 reforms, rather than to examine one disease state or drug at a time. Our AMA supports value-based pricing programs, initiatives and mechanisms for pharmaceuticals that are guided by the following principles: (a) value-based prices of pharmaceuticals should be determined by objective, independent entities; (b) value-based prices of pharmaceuticals should be evidence-based and be the result of valid and reliable inputs and data that incorporate rigorous scientific methods, including clinical trials, clinical data registries, comparative effectiveness research, and robust outcome measures that capture short-and long-term clinical outcomes; (c) processes to determine value-based prices of pharmaceuticals must be transparent, easily accessible to physicians and patients, and provide practicing physicians and researchers a central and significant role; (d) processes to determine value-based prices of pharmaceuticals should limit administrative burdens on physicians and patients; (e) processes to determine value-based prices of pharmaceuticals should incorporate affordability criteria to help assure patient affordability as well as limit system-wide budgetary impact; and (f) value-based pricing of pharmaceuticals should allow for patient variation and physician discretion. 2. Our AMA supports the inclusion of the cost of alternatives and cost-effectiveness analysis in comparative effectiveness research. 3. Our AMA supports direct purchasing of pharmaceuticals used to treat or cure diseases that pose unique public health threats, including hepatitis C, in which lower drug prices are assured in exchange for a guaranteed market size. Policy Timeline CMS Rep. 05, I-16 Reaffirmed in lieu of: Res. 207, A-17 Reaffirmed: CMS-CSAPH Rep. 01, A-17 H-110.987 Pharmaceutical Costs 1. Our AMA encourages Federal Trade Commission (FTC) actions to limit anticompetitive behavior by pharmaceutical companies attempting to reduce competition from generic manufacturers through manipulation of patent protections and abuse of regulatory exclusivity incentives. 2. Our AMA encourages Congress, the FTC and the Department of Health and Human Services to monitor and evaluate the utilization and impact of controlled distribution channels for prescription pharmaceuticals on patient access and market competition. 3. Our AMA will monitor the impact of mergers and acquisitions in the pharmaceutical industry. 4 . Our AMA will continue to monitor and support an appropriate balance between incentives based on appropriate safeguards for innovation on the one hand and efforts to reduce regulatory and statutory barriers to competition as part of the patent system. 5. Our AMA encourages prescription drug price and cost transparency among pharmaceutical companies, pharmacy benefit managers and health insurance companies. 6. Our AMA supports legislation to require generic drug manufacturers to pay an additional rebate to state Medicaid programs if the price of a generic drug rises faster than inflation. 7. Our AMA supports legislation to shorten the exclusivity period for biologics. 8. Our AMA will convene a task force of appropriate AMA Councils, state medical societies and national medical specialty societies to develop principles to guide advocacy and grassroots efforts aimed at addressing pharmaceutical costs and improving patient access and adherence to medically necessary prescription drug regimens. 9. Our AMA will generate an advocacy campaign to engage physicians and patients in local and national advocacy initiatives that bring attention to the rising price of prescription drugs and help to put forward solutions to make prescription drugs more affordable for all patients. 10. Our AMA supports: (a) drug price transparency legislation that requires pharmaceutical manufacturers to provide public notice before increasing the price of any drug (generic, brand, or specialty) by 10% or more each year or per course of treatment and provide justification for the price increase; (b) legislation that authorizes the Attorney General and/or the Federal Trade Commission to take legal action to address price gouging by pharmaceutical manufacturers and increase access to affordable drugs for patients; and (c) the expedited review of generic drug applications and prioritizing review of such applications when there is a drug shortage, no available comparable generic drug, or a price increase of 10% or more each year or per course of treatment. 
H-110.990 Cost Sharing Arrangements for Prescription Drugs
Our AMA: 1. believes that cost-sharing arrangements for prescription drugs should be designed to encourage the judicious use of health care resources, rather than simply shifting costs to patients; 2. believes that cost-sharing requirements should be based on considerations such as: unit cost of medication; availability of therapeutic alternatives; medical condition being treated; personal income; and other factors known to affect patient compliance and health outcomes; and 3. supports the development and use of tools and technology that enable physicians and patients to determine the actual price and out-of-pocket costs of individual prescription drugs prior to making prescribing decisions, so that physicians and patients can work together to determine the most efficient and effective treatment for the patient's medical condition. 
